Clinical Trial

The Origin and Role of Thromboembolism in the Pathogenesis of Ischaemic Stroke

Study acronym: TORPIS
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated December 2, 2025 (before its estimated August 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
Ischaemic stroke is usually due to occlusion of a cerebral artery by thrombus. However, it is often difficult to identify the source of thrombus, or to confirm thrombus as a cause of ischaemic stroke. Moreover, it is debated whether thrombosis plays any role in certain types of stroke such as lacunar stroke. In preliminary studies, the investigators have evaluated a novel clinical grade thrombus-specific radiotracer, 18F-GP1, which has a high specificity for the glycoprotein IIb/IIIa receptor on activated platelets. The investigations have demonstrated that 18F-GP1 is highly sensitive to in vivo thrombus formation and demonstrates avid binding to thrombus associated with myocardial infarction, pulmonary embolism and aortic bioprosthesis. This study will use this imaging approach to define the role and origin of thrombus in patients with ischaemic stroke, cryptogenic stroke and lacunar stroke.The investigators will also assess its added clinical value in assessing patients with ischaemic stroke.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2022-11-23; most recent amendment 2025-12-01.
Status change: Not Yet Recruiting → Recruiting 2023-04-20
Trial Details
NCT Number NCT05636748
Lead Sponsor University of Edinburgh
Collaborators: British Heart Foundation
Conditions Stroke, PET, Thrombosis
Enrollment 120 participants
Start Date 2023-02-28
Primary Completion 2026-08-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-02